FDA Lifts Clinical Hold on KEYNOTE-B79 Trial of a Novel CAR T-Cell Agent in mCRC

The CYAD-101-002 trial may resume after the FDA lifted the partial clinical hold to evaluate risk to study patients with metastatic colorectal cancer. The FDA has lifted the clinical hold on the phase 1b CYAD-101-002 trial (KEYNOTE-B79; NCT04991948), which is evaluating the safety and clinical activity of the investigational chimeric antigen receptor (CAR T)-cell therapy …

FDA Lifts Clinical Hold on KEYNOTE-B79 Trial of a Novel CAR T-Cell Agent in mCRC Read More »